Home Featured Page 144

Featured

Latest

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

FILAMENT HEALTH ANNOUNCES NEW UNITED STATES PATENT ISSUANCES

Revive Therapeutics Ltd. Announces Offering of Up to $5 Million

Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming...

Many Trips, Diminishing Returns: Cross-Tolerance Between LSD and DOI

PT375 – Microdosing & Citizen Science: Introducing the World’s First Take-Home...

Small Pharma to Participate in November Investor and Healthcare Conferences

Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human...

Tryp Therapeutics Announces Poster Presentations on the Reduction of Chronic Pain...

Psychedelics Weekly – Bipartisan Political Movement & Psychedelics and Pain

How To Stop A Psychedelic Trip: The Promise of Ketanserin

EDITOR PICKS

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s;...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

Psychedelics & Society

FILAMENT HEALTH ANNOUNCES NEW UNITED STATES PATENT ISSUANCES

Revive Therapeutics Ltd. Announces Offering of Up to $5 Million

Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming...

Many Trips, Diminishing Returns: Cross-Tolerance Between LSD and DOI

PT375 – Microdosing & Citizen Science: Introducing the World’s First Take-Home...

Small Pharma to Participate in November Investor and Healthcare Conferences

Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human...

Tryp Therapeutics Announces Poster Presentations on the Reduction of Chronic Pain...

Psychedelics Weekly – Bipartisan Political Movement & Psychedelics and Pain

How To Stop A Psychedelic Trip: The Promise of Ketanserin

EDITOR PICKS

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s;...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY